Floatz logo

ik-595

CRAF Gene Mutation

Ikena OncologyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the CRAF Gene Mutation cohort.

Asset / SponsorPhaseRating
Dcc-3084
Deciphera Pharmaceuticals, LLC
Phase 1CC

Same molecule, other indications

ik-595 is also rated in:

Ras (Kras or Nras) Gene MutationDormant
CC
Indicative ·
43 / 100
View asset →
BRAF Gene MutationDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →